Citable company snapshot
Charles River Laboratories's latest SEC-sourced 2026-03-28 period shows $995.83M in revenue and $-14.84M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 28, 2026 | $995.83M | $994.23M | +0.2% |
| xbrl:GrossProfit | Dec 26, 2020 | $299.97M | $289.27M | +3.7% |
| xbrl:OperatingIncomeLoss | Mar 28, 2026 | $119.90M | $-283.44M | +142.3% |
| xbrl:NetIncomeLoss | Mar 28, 2026 | $-14.84M | $-276.56M | +94.6% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 28, 2026 | $41.08M | $147.52M | -72.2% |
| Free Cash Flow (computed) | Mar 28, 2026 | $-14.83M | $58.57M | -125.3% |
Source: SEC EDGAR XBRL; period Mar 28, 2026; filed May 7, 2026; accession 0001100682-26-000038.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
